Journal List > Tuberc Respir Dis > v.57(4) > 1000695

TOOLS
Lee, Seo, Lee, Huh, Choi, Park, Shim, Oh, Park, Ryu, and Choi: Effect of Beraprost Sodium in Patients with Chronic Obstructive Pulmonary Disease
Original Article

Tuberculosis and Respiratory Diseases 2004; 57(4): 320-328.

Published online: 31 October 2004

DOI: https://doi.org/10.4046/trd.2004.57.4.320

Effect of Beraprost Sodium in Patients with Chronic Obstructive Pulmonary Disease

Sang-Do Lee, M.D., Kwang Won Seo, M.D., Jung Yeon Lee, M.D., Jin Won Huh, M.D., Ik Su Choi, M.D., Jae Sun Park, M.D., Tae Sun Shim, M.D., Yeon-Mok Oh, M.D., In Won Park, M.D.1, Wang-Seong Ryu, M.D.2, Byoung Whui Choi, M.D.1

Division of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

1Division of Pulmonology and Allergy, Department of Internal Medicine, Chung Ang University,College of Medicine, Yongsan Hospital, Seoul, Korea.

2Division of Cardiology, Department of Internal Medicine, Chung Ang University,College of Medicine, Yongsan Hospital, Seoul, Korea.

Address for correspondence: Byoung Whui Choi, M.D. Division of Pulmonology and Allergy, Department of Internal Medicine, Chung Ang University, College of Medicine, Yongsan Hospital, 65-207, 3 Ka Hangang-Ro, Yongsan-Gu, Seoul 140-757, Korea. Phone: 02-748-9878, Fax: 02-798-4745, bwchoimd@ nownuri.net

Received 5 August 2004       Accepted 21 September 2004

Copyright©2004. The Korean Academy of Tuberculosis and Respiratory Diseases. All rights reserved.

Abstract

Background

Pulmonary vascular changes which occur early in the course of chronic obstructive pulmonary disease (COPD) are prevalent manifestation and later cause pulmonary hypertension, which is a bad prognostic factor in COPD. Beraprost sodium (BPS), an orally active prostacyclin analogue, has been shown to improve survival in patients with primary pulmonary hypertension. This study investigated the effect of BPS in the patients with COPD.

Methods

This is a double-blind randomized placebo-controlled, two center clinical trial. Twenty one consecutive patients with COPD were enrolled from June 2003 to June 2004 (patients treated with BPS for 3 months, BPS group, n=11; those with placebo, placebo group, n=10). The baseline demographic, pulmonary function and hemodynamic data were not significantly different between two groups.

Results

On echocardiographic examination, trans tricuspid valve pressure gradient has decreased significantly after 3 months with beraprost in the BPS group [17.7(±11.4) to 8.2(±8.9) mm Hg, p-value<0.05], while there was no significant change in the control group. Six-minute walking distance has decreased in the control group and increased in the BPS group, but there was no statistical significance.

Conclusion

In patients with COPD oral administration of BPS reduced the pulmonary arterial pressure. The clinical significance of this finding, that is improving symptoms and natural course of the disease, needs further study.

Keywords: Beraprost sodium, COPD, Pulmonary hypertension

TOOLS
Similar articles